EyePoint Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
EyePoint Pharmaceuticals's earnings have been declining at an average annual rate of -9.8%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 20.8% per year.
Key information
-9.8%
Earnings growth rate
32.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 20.8% |
Return on equity | -31.6% |
Net Margin | -157.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How EyePoint Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 50 | -79 | 50 | 0 |
31 Dec 23 | 46 | -71 | 51 | 0 |
30 Sep 23 | 43 | -100 | 55 | 0 |
30 Jun 23 | 37 | -106 | 59 | 0 |
31 Mar 23 | 40 | -102 | 60 | 0 |
31 Dec 22 | 41 | -102 | 60 | 0 |
30 Sep 22 | 42 | -78 | 64 | 0 |
30 Jun 22 | 41 | -77 | 62 | 0 |
31 Mar 22 | 39 | -67 | 58 | 0 |
31 Dec 21 | 37 | -58 | 54 | 0 |
30 Sep 21 | 33 | -54 | 48 | 0 |
30 Jun 21 | 39 | -42 | 45 | 0 |
31 Mar 21 | 34 | -44 | 44 | 0 |
31 Dec 20 | 34 | -45 | 46 | 0 |
30 Sep 20 | 36 | -40 | 46 | 0 |
30 Jun 20 | 23 | -52 | 47 | 0 |
31 Mar 20 | 26 | -51 | 48 | 0 |
31 Dec 19 | 20 | -57 | 48 | 0 |
30 Sep 19 | 14 | -58 | 45 | 0 |
30 Jun 19 | 12 | -75 | 41 | 0 |
31 Mar 19 | 6 | -98 | 35 | 0 |
31 Dec 18 | 5 | -86 | 25 | 0 |
30 Sep 18 | 3 | -80 | 18 | 0 |
30 Jun 18 | 3 | -53 | 13 | 0 |
31 Mar 18 | 3 | -25 | 10 | 0 |
31 Dec 17 | 3 | -23 | 10 | 0 |
30 Sep 17 | 8 | -17 | 9 | 0 |
30 Jun 17 | 8 | -18 | 11 | 0 |
31 Mar 17 | 7 | -19 | 10 | 0 |
31 Dec 16 | 7 | -19 | 10 | 0 |
30 Sep 16 | 1 | -24 | 10 | 0 |
30 Jun 16 | 2 | -22 | 9 | 0 |
31 Mar 16 | 2 | -20 | 9 | 0 |
31 Dec 15 | 2 | -20 | 8 | 0 |
30 Sep 15 | 2 | -19 | 8 | 0 |
30 Jun 15 | 27 | 6 | 8 | 0 |
31 Mar 15 | 26 | 8 | 8 | 0 |
31 Dec 14 | 28 | 10 | 8 | 0 |
30 Sep 14 | 28 | 11 | 7 | 0 |
30 Jun 14 | 3 | -13 | 7 | 0 |
31 Mar 14 | 4 | -13 | 8 | 0 |
31 Dec 13 | 2 | -14 | 7 | 0 |
30 Sep 13 | 2 | -13 | 7 | 0 |
30 Jun 13 | 2 | -12 | 7 | 0 |
Quality Earnings: PV3B is currently unprofitable.
Growing Profit Margin: PV3B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PV3B is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare PV3B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PV3B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: PV3B has a negative Return on Equity (-31.57%), as it is currently unprofitable.